- This Week in Biopharma Deals, by biodealroom
- Posts
- Big Pharma Wraps 2024 with a Deal-Making Bow
Big Pharma Wraps 2024 with a Deal-Making Bow
Week 50 Deals (2024)
Deal of the Week: AbbVie & Nimble Therapeutics Merge for Immunology Boost (PRNewswire)
Oral peptides supercharge psoriasis pipeline
Structure: Acquisition
Date Announced: December 12, 2024
Total Deal Value: $200 million
Upfront Cash: $200 million
Therapeutic Modality: Oral peptide IL23R inhibitor
Therapeutic Area: Psoriasis, immunology
Phase: Preclinical
Notable Deals
Cimeio Therapeutics & Kyowa Kirin Partner for Cell Therapies (BusinessWire)
Shielded cell therapies target oncology
Structure: Partnership and licensing agreement
Date Announced: December 9, 2024
Total Deal Value: Up to $3 billion
Upfront Cash: $50 million
Total Milestones: Up to $2.95 billion
Therapeutic Modality: Shielded cell therapies
Therapeutic Area: Oncology
Phase: Preclinical
LVMH Recherche & Integrated Biosciences Team Up for AI Research (BusinessWire)
AI-driven drug discovery gets luxe backing
Structure: Strategic research partnership
Date Announced: December 9, 2024
Key Terms: Collaboration leverages Integrated Biosciences’ AI platform for novel drug targets; no financial terms disclosed
Asahi Kasei Pharma Licenses anti-CX3CR1 Antibody Globally (BusinessWire)
Neuroinflammatory treatment gains traction
Structure: Exclusive global licensing agreement
Date Announced: December 11, 2024
Total Deal Value: Up to $1.7 billion
Upfront Cash: $50 million
Total Milestones: Up to $1.65 billion
Therapeutic Modality: Monoclonal antibody
Therapeutic Area: Neuroinflammatory diseases
Phase: Preclinical
BeiGene & Porton Pharma Solutions/Aojin Life Sciences Collaborate on XDC Drugs (BusinessWire)
Dual IND filings boost conjugate drug pipeline
Structure: Strategic collaboration for XDC conjugate drugs
Date Announced: December 10, 2024 (Porton/Aojin); December 12, 2024 (BeiGene)
Total Deal Value: Undisclosed
Key Terms: Partnership aims for simultaneous IND filings in China and U.S. for novel conjugate drugs; no financial terms disclosed
Orion Corporation & Evariste Design Novel Inhibitors (BusinessWire)
Undisclosed target gets fresh attention
Structure: Collaboration agreement
Date Announced: December 10, 2024
Key Terms: Partnership focuses on designing inhibitors for an undisclosed target using Evariste’s platform; no financial terms disclosed
Relation & GSK Forge Paths for Fibrotic Diseases, Osteoarthritis (GlobeNewswire)
RNA-targeting therapies tackle chronic conditions
Structure: Two strategic collaborations
Date Announced: December 10, 2024
Total Deal Value: Up to $700 million (combined)
Upfront Cash: $75 million (combined)
Total Milestones: Up to $625 million
Therapeutic Modality: RNA-targeting therapies
Therapeutic Area: Fibrotic diseases, osteoarthritis
Phase: Preclinical
Tanner Pharma & Agenus Expand Access to Cancer Therapies (BusinessWire)
Botensilimab, Balstilimab reach new markets
Structure: Partnership agreement
Date Announced: December 11, 2024
Key Terms: Tanner Pharma to distribute Agenus’ Botensilimab and Balstilimab globally, enhancing access for cancer patients; no financial terms disclosed
Elevation Oncology Licenses ADC Tech from Synaffix (PRNewswire)
ADC pipeline expansion targets solid tumors
Structure: Licensing agreement
Date Announced: December 11, 2024
Total Deal Value: Up to $225 million
Upfront Cash: $10 million
Total Milestones: Up to $215 million
Therapeutic Modality: Antibody-drug conjugate (ADC)
Therapeutic Area: Solid tumors
Phase: Preclinical